Key result
Noninvasive, transcutaneous vagus nerve stimulation is proposed as a potential adjuvant therapy to decrease gastrointestinal inflammation in patients with inflammatory bowel disease.
Why the study?
Does noninvasive transcutaneous vagus nerve stimulation reduce gastrointestinal inflammation in patients with inflammatory bowel disease?
Does noninvasive transcutaneous vagus nerve stimulation reduce gastrointestinal inflammation in patients with inflammatory bowel disease?
Transcutaneous vagus nerve stimulation is proposed as a potential non-pharmacological adjuvant therapy to reduce inflammation in inflammatory bowel disease.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for transcutaneous vagus nerve stimulation in IBD; leaves open need for RCTs before any clinical role.
Crohn's disease and ulcerative colitis are the primary inflammatory bowel diseases (IBDs) affecting the gastrointestinal tract. The current therapy aims at decreasing inflammation and reducing symptoms. This typically requires immune suppression by steroids, thiopurines, methotrexate, or tumor necrosis factor inhibitors. Patients may be unreceptive to medical therapy, and some may discontinue the treatment due to adverse effects. Noninvasive, transcutaneous vagus nerve stimulation (VNS) is currently used as a treatment for depression and epilepsy, and it is being investigated for the treatment of conditions such as multiple sclerosis, migraines, and Alzheimer's disease. Recent studies have demonstrated the importance of splenic and vagus nerve functions in the inflammatory process through the production of certain cytokines. We hypothesize that using transcutaneous VNS via the auricular afferent branch could achieve a selective anti-inflammatory effect on the intestinal wall. This review examines the possibility of using vagal stimulators as a therapy for IBD. This could open the door to novel treatments for numerous vagally mediated diseases characterized by poor responses to current therapies.
No takes yet. Share an insight, caveat, or question.
Marshall et al. (2015) conducted a review in Inflammatory Bowel Disease. Transcutaneous vagus nerve stimulation (VNS) was evaluated. Noninvasive, transcutaneous vagus nerve stimulation is proposed as a potential adjuvant therapy to decrease gastrointestinal inflammation in patients with inflammatory bowel disease.
Synapse has enriched 10 related papers. Consider them for comparative context: